BACKGROUND: BRCA1 gene-related tumours are more frequently estrogen receptor (ER) and progesterone receptor (PR) negative with a lower prevalence of human epidermal growth factor receptor 2 (HER2) overexpression or amplification. We evaluated the effectiveness of a combination of homogeneously selected criteria and immunohistochemical (IHC) characteristics of Familial Breast Cancers (FBCs) in detecting BRCA1 mutation carriers. METHODS: Primary breast tumours from 93 FBC patients defined by specific eligibility criteria, based on personal and familial tumour history, were evaluated by Allred's method. The BRCA1 molecular analysis, including Multiplex Ligation-dependent Probe Amplification (MLPA), was considered as the gold standard assay. RESULTS: A total of 10 BRCA1 pathogenetic mutations was found. With the exclusion of the tumours characterized by double positive receptorial status and/or strong HER2 positivity (3+), we identified 22 patients, 10 of whom resulted as BRCA1 mutation carriers. The sensitivity, specificity, positive and negative predictive values were 100%, 83.3%, 45.4% and 100% respectively. CONCLUSION: Our findings suggest that the IHC analysis by Allred's method improves our ability to select patients for BRCA1 testing.
BACKGROUND:BRCA1 gene-related tumours are more frequently estrogen receptor (ER) and progesterone receptor (PR) negative with a lower prevalence of humanepidermal growth factor receptor 2 (HER2) overexpression or amplification. We evaluated the effectiveness of a combination of homogeneously selected criteria and immunohistochemical (IHC) characteristics of Familial Breast Cancers (FBCs) in detecting BRCA1 mutation carriers. METHODS:Primary breast tumours from 93 FBC patients defined by specific eligibility criteria, based on personal and familial tumour history, were evaluated by Allred's method. The BRCA1 molecular analysis, including Multiplex Ligation-dependent Probe Amplification (MLPA), was considered as the gold standard assay. RESULTS: A total of 10 BRCA1 pathogenetic mutations was found. With the exclusion of the tumours characterized by double positive receptorial status and/or strong HER2 positivity (3+), we identified 22 patients, 10 of whom resulted as BRCA1 mutation carriers. The sensitivity, specificity, positive and negative predictive values were 100%, 83.3%, 45.4% and 100% respectively. CONCLUSION: Our findings suggest that the IHC analysis by Allred's method improves our ability to select patients for BRCA1 testing.
Authors: S A Vaziri; L M Krumroy; P Elson; G T Budd; G Darlington; J Myles; R R Tubbs; G Casey Journal: Clin Cancer Res Date: 2001-07 Impact factor: 12.531
Authors: Antonino Musolino; Maria A Bella; Beatrice Bortesi; Maria Michiara; Nadia Naldi; Paola Zanelli; Marzia Capelletti; Debora Pezzuolo; Roberta Camisa; Mario Savi; Tauro M Neri; Andrea Ardizzoni Journal: Breast Date: 2007-01-25 Impact factor: 4.380
Authors: Helen A Shih; Fergus J Couch; Katherine L Nathanson; M Anne Blackwood; Timothy R Rebbeck; Katrina A Armstrong; Kathleen Calzone; Jill Stopfer; Sheila Seal; Michael R Stratton; Barbara L Weber Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: C Capalbo; E Ricevuto; A Vestri; E Ristori; T Sidoni; O Buffone; B Adamo; E Cortesi; P Marchetti; G Scambia; S Tomao; C Rinaldi; M Zani; S Ferraro; L Frati; I Screpanti; A Gulino; G Giannini Journal: Ann Oncol Date: 2006-06 Impact factor: 32.976
Authors: Ana Osorio; Miguel de la Hoya; Raquel Rodríguez-López; Angel Martínez-Ramírez; Alicia Cazorla; Juan José Granizo; Manel Esteller; Carmen Rivas; Trinidad Caldés; Javier Benítez Journal: Int J Cancer Date: 2002-05-10 Impact factor: 7.396